U.S. CDC reports 215,194 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Wednesday reported 7.8 million cases of the new coronavirus, an increase of 47,459 from its previous count, and said the number of deaths had risen by 748 to 215,194.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by the new coronavirus, as of 4 pm ET on Oct. 13 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D’Silva)

Countries turn to rapid antigen tests to contain second wave of COVID-19

By John Miller, Caroline Copley and Bart H. Meijer

ZURICH/BERLIN (Reuters) – Countries straining to contain a second wave of COVID-19 are turning to faster, cheaper but less accurate tests to avoid the delays and shortages that have plagued efforts to diagnose and trace those infected quickly.

Germany, where infections jumped by 4,122 on Tuesday to 329,453 total, has secured 9 million so-called antigen tests per month that can deliver a result in minutes and cost about 5 euros ($5.90) each. That would, in theory, cover more than 10% of the population.

The United States and Canada are also buying millions of tests, as is Italy, whose recent tender for 5 million tests attracted offers from 35 companies. Switzerland, where new COVID-19 cases are at record levels, is considering adding the tests to its nationwide screening strategy.

Germany’s Robert Koch Institute (RKI) now recommends antigen tests to complement existing molecular PCR tests, which have become the standard for assessing active infections but which have also suffered shortages as the pandemic overwhelmed laboratories and outstripped manufacturers’ production capacity.

PCR tests detect genetic material in the virus while antigen tests detect proteins on the virus’s surface, though both are meant to pick up active infections. Another type of test, for antibodies the body produces in response to an infection, can help tell if somebody has had COVID-19 in the past.

Like PCR (polymerase chain reaction) tests, antigen tests require an uncomfortable nasal swab. They can also produce more “false negatives,” prompting some experts to recommend they only be used in a pinch.

Still, the alarming rise in new infections globally has health officials desperately pursuing more options as the winter influenza season looms.

The World Health Organization reported more than 2 million new cases last week, bringing the total worldwide to 37 million, with more than 1 million deaths from COVID-19.

“These point-of-care tests could make a big difference,” said Gerard Krause, epidemiology department director at Germany’s Helmholtz Centre for Infection Research.

NO TEST NO FLIGHT

Krause said low-priority patients – those without symptoms – could initially be screened with antigen tests, leaving the more accurate PCR tests for those showing signs of the disease.

Antigen tests have already gained traction in the travel industry. Italian airline Alitalia offers Rome-Milan flights exclusively for passengers with negative tests and Germany’s Lufthansa has announced similar testing plans.

But the pandemic’s vast scale has strained the ability of countries to test all of their citizens, making it difficult to track the twisting paths of infection comprehensively and prevent a resurgence.

In the United States, for example, reliance on automated PCR machinery over the summer left many patients frustrated as they waited for a week or more for results.

Testing in Europe has also suffered glitches.

France does over a million tests a week but its free-for-all testing policy has led to long queues and delays in results, prompting French researchers to come up with a test they say can produce results in 40 minutes, without using a swab.

Italy does between 800,000 and 840,000 tests a week, more than double April’s levels, according to the Ministry of Health. But a government adviser, University of Padua microbiology professor Andrea Crisanti, said the country needs 2 million tests a week to really get on top of the virus.

In the Netherlands, where infection rates are among Europe’s highest, the government has been scrambling to expand weekly testing and lab capacity to 385,000 by next week from 280,000 now. The target is nearly half a million tests a week by December and just under 600,000 by February.

But people have been waiting days for a test. The authorities blame the overwhelming demand from those without clear symptoms for clogging up the system.

In response, the authorities have restricted rapid antigen tests to health workers and teachers, while others go on a waiting list.

‘GOLD STANDARD’

The various hitches highlight a conundrum for governments: how to get people back to work while tracing the virus within the population quickly – without running out of supplies.

Siemens Healthineers, which on Wednesday announced the launch of a rapid antigen test kit in Europe that can deliver a result in 15 minutes, said the volumes of such diagnostic tests being circulated globally now are “at the limits” of what manufacturers can supply.

Rivals including Abbott Laboratories and Becton Dickinson also offer numerous COVID-19 diagnostic tests, with more and more companies jumping in.

Swiss diagnostics maker Roche, announced plans on Tuesday to launch a new antigen test by the end of the year. Its fully automated systems can provide a test result in 18 minutes and a single lab machine can process 300 tests an hour.

By early 2021, the Basel-based company said it could make some 50 million of the new tests a month, on top of the rapid point-of-care tests it already sells.

Roche said the test could be deployed in places such as nursing homes or hospitals, where speedy results could thwart a potentially lethal outbreak.

“The primary use case is the testing of symptomatic patients,” a Roche spokeswoman said. “The secondary use case is the testing of individuals suspected of infection … which could also include asymptomatic patients.”

Expert opinion, however, on just how to use antigen tests is evolving and remains the subject of debate.

Switzerland, where reported new infections spiked to 2,823 cases on Wednesday from as low as three per day in June, is only now validating the accuracy of the rapid tests.

“Deployment of the rapid tests – where it makes sense – will be integrated into our testing strategy,” a spokesman for the Swiss federal health ministry said. “We’ll update our testing recommendations in November.”

Sandra Ciesek, director of the Institute of Medical Virology at the University Clinic in Frankfurt, Germany said rapid antigen tests could be an option for asymptomatic patients planning to visit elderly patients at nursing homes.

But people should refrain from using them as a definitive substitute to judge their infection status.

“The PCR test remains the gold standard,” Ciesek said. “An antigen test should only be used as an alternative if PCR is not possible in a timely manner.”

(Reporting by John Miller in Zurich, Caroline Copley in Berlin, Emilio Parodi and Giselda Vagnoni in Milan, Josephine Mason in London, Bart Meijer in Amsterdam and Matthias Blamont in Paris; Editing by David Clarke)

NIH starts clinical trial testing antibody treatments in COVID-19 patients

(Reuters) – The U.S. National Institutes of Health (NIH) said on Tuesday it has started a study to evaluate two antibody treatments in COVID-19 patients as part of the agency’s program to identify promising drugs to help tackle the new coronavirus.

The trial will test AbbVie Inc’s psoriasis drug risankizumab along with Gilead Sciences’ antiviral remdesivir, compared to a placebo and remdesivir.

The study will also test Humanigen’s experimental drug lenzilumab with remdesivir, compared to placebo and remdesivir.

“The goal here is to identify as quickly as possible the experimental therapeutics that demonstrate the most clinical promise as COVID-19 treatments and move them into larger-scale testing,” said NIAID Director and U.S. infectious diseases expert Anthony Fauci.

Gilead’s remdesivir, which was among the first to be used to treat COVID-19 and received emergency use authorization from the U.S. Food and Drug Administration in May, has since been authorized for use in several other countries.

Risankizumab and lenzilumab belong to a class of drugs known as monoclonal antibodies that are laboratory-made versions of proteins naturally produced by the immune system in response to invading viruses or other pathogens.

The treatment has come under the spotlight after U.S. President Donald Trump was treated with Regeneron Pharmaceuticals’ antibody drug earlier this month.

Regeneron and Eli Lilly have both applied to the U.S. FDA for emergency use of their antibody treatments.

(Reporting by Amruta Khandekar; editing by Ankur Banerjee and Ramakrishnan M.)

U.S. CDC reports 214,446 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday reported 7,787,548 cases of the new coronavirus, an increase of 46,614 from its previous count, and said that the number of deaths had risen by 338 to 214,446.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 pm ET on Oct. 12 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Dania Nadeem in Bengaluru; Editing by Devika Syamnath)

Humanitarian crisis feared as Nagorno-Karabakh ceasefire buckles

By Nvard Hovhannisyan and Nailia Bagirova

YEREVAN/BAKU (Reuters) – Armenia and Azerbaijan accused each other on Tuesday of violating a ceasefire agreed three days ago to quell fighting over Nagorno-Karabakh, drawing warnings from international groups of a humanitarian crisis in the region.

The Russia-brokered truce is buckling despite mounting calls from world powers to halt the fighting, with U.S. Secretary of State Mike Pompeo and the Minsk Group security watchdog among those urging greater commitment to the ceasefire terms.

A Reuters cameraman witnessed shelling in the town of Martuni in Nagorno-Karabakh, a mountain enclave which is internationally recognized as part of Azerbaijan but governed and populated by ethnic Armenians.

A Reuters television crew in Terter in Azerbaijan also said the city center was being shelled earlier on Tuesday.

Azerbaijan accused Armenian forces of “grossly violating the humanitarian truce”, which was agreed on Saturday to allow the sides to swap prisoners and bodies of those killed..

Defense ministry spokesman Vagif Dargiahly said Armenia was shelling the Azeri territories of Goranboy and Aghdam, as well as Terter. Azeri forces were not violating the truce, he added.

Armenian defense ministry spokeswoman Shushan Stepanyan denied the accusation. She said Azeri forces had resumed military operations after an overnight lull, “supported by active artillery fire in the southern, northern, northeastern and eastern directions”.

The fighting which erupted on Sept. 27, is the worst since a 1991-94 war over Nagorno-Karabakh that killed about 30,000.

It is being closely watched abroad, not only due to its proximity to Azeri energy pipelines to Europe but also because of fears that Russia and Turkey could be drawn in.

Russia has a defense pact with Armenia and Turkey is allied with Azerbaijan.

“CATASTROPHIC CONSEQUENCES”

The Minsk Group called on the Armenian and Azeri leaders to immediately implement the ceasefire to prevent “catastrophic consequences for the region”.

The 11-member group includes both Russia and Turkey, but the latter is not involved in the Nagorno-Karabakh talks. Turkish Foreign Minister Mevlut Cavusoglu suggested holding talks that would include Turkey.

Ceasefire demands were “reasonable,” according to Cavusoglu, but he said the international community should ask Armenia to withdraw from Azeri territory.

“Sadly no such call is being made,” he told reporters.

Influential Turkish politician Devlet Bahceli, whose party supports President Erdogan’s AKP in parliament, took a more belligerent note, telling Azerbaijan to secure Nagorno-Karabakh by “hitting Armenia over the head over and over again.”

While Turkey denies military involvement in Nagorno-Karabakh, Armenian President Armen Sarkissian told Germany’s Bild newspaper Ankara’s behavior was worrying.

“I worry because, firstly, there is a third party involved. If it were only about Nagorno-Karabakh and Azerbaijan, I would be much more hopeful that the conflict can be contained,” he said.

DEAD AND WOUNDED

The death toll has risen further, meanwhile. Nagorno-Karabakh officials said 542 servicemen had been killed so far, up 17 from Monday.

Azerbaijan has reported 42 Azeri civilian deaths and 206 wounded since Sept. 27. It has not disclosed military casualties.

Martin Schuepp, Eurasia regional director for the International Committee of the Red Cross (ICRC), said his organization was in “continuous discussions” to facilitate the handover of detainees or bodies of those killed.

But the security situation meant “it has not been possible for us to access all locations that might have been affected,” Schuepp said.

The conflict is also worsening the spread of COVID-19, World Health Organization spokesman Tarik Jasarevic told a United Nations briefing in Geneva.

Armenia’s new cases had doubled over the past 14 days as of Monday, while new infections were up approximately 80% over the past week in Azerbaijan, Jasarevic said. He warned of “direct disruption to health care and a further burden on health systems that are already stretched during the COVID pandemic.”

With tens of thousands of people potentially needing help in coming months, the ICRC is appealing for another 9.2 million Swiss francs ($10.10 million) to fund its humanitarian efforts in the region, Schuepp said.

(Additional reporting by Margarita Antidze in Tbilisi, Riham Alkousaa in Berlin, Stephanie Ulmer-Nebehay in Geneva, Tuvan Gumrukcu and Jonathan Spicer in Ankara; Writing by Sujata Rao; Editing by Giles Elgood, Timothy Heritage, William Maclean)

How poor regions lose out because of U.S. census undercounts

By Nick Brown

ESPANOLA, New Mexico (Reuters) – Getting an accurate count of America’s population has proven difficult in the 2020 Census as the coronavirus pandemic has hampered voluntary responses and forced officials to scale back door-knocking efforts.

The administration of President Donald Trump has placed other hurdles on the path to an accurate count. Its attempt to add a question about citizenship to the census earlier this year likely discouraged undocumented immigrants from filling out the survey, even though the administration’s effort failed, demographics experts say. Local officials nationwide worry about the impact of undercounts on their communities.

“This is going to be the worst response rate we’ve ever had,” said Lauren Reichelt, Health and Human Services Director for Rio Arriba County, New Mexico.

Rio Arriba is typical of other regions across the United States that are hardest to count – and have the most to lose from an undercount. It’s poor, rural and home to many undocumented immigrants. Low population tallies can rob such areas of badly needed federal dollars for affordable housing and child care, for instance, or resources to fight America’s opioid epidemic, according to local officials in some of the most undercounted regions in the last census, taken in 2010.

“Persistent undercounting in communities that would benefit most from targeted public and private investment makes it harder to address the very barriers that contribute to a less accurate census,” said Terri Ann Lowenthal, a consultant on census and statistical issues and former congressional staffer overseeing census matters.

The Census Bureau and the White House declined to comment for this story.

The Bureau is nearing the end of the 2020 edition of the decennial count, which will guide the allocation of $1.5 trillion a year in federal aid. The census is also a linchpin of American democracy because the population counts are used to determine the number of Congressional representatives assigned to a state and to draw maps of electoral districts.

Some of the hardest-to-count regions in the last census might be even harder to survey this year as the country reels from the coronavirus pandemic, according to a Reuters analysis of Census data. They include border areas in Texas, the lowlands of Mississippi and the northern plains of New Mexico.

‘I ALWAYS RELAPSE’

Rio Arriba officials estimated they were undercounted by 4% in 2010, after only 42% of households mailed back their census forms voluntarily. That compared to 66.5% of households that responded by mail nationally, according to Census data.

The bureau sent door-knockers to get more responses, but still had to use a Census process called imputation to estimate residency for 9.6% of Rio Arriba’s count, a far larger proportion than the national average.

Officials in the county say an accurate count would have helped narrow funding gaps that leave it without enough medicine, detox clinics, housing and other support to fight one of the community’s biggest problems: an opioid epidemic that kills people at a rate more than four times the U.S. average, according to government data.

The current U.S. Census shows no signs of reversing the trend. Rio Arriba’s voluntary response rate is running at 32%, 10 points below its 2010 rate and less than half the overall U.S. rate of 67%.

It is impossible to know exactly how much funding is lost due to an undercount, says George Washington University professor Andrew Reamer, the nation’s foremost expert on the relationship between the census and federal spending. That would require knowing exactly how many people were missed and which government programs would have served them.

Officials in Rio Arriba agree they were entitled to more federal funds for programs to address a local opioid crisis.

“A lot of the funding for my department is federal, so we end up being entitled to a lot less than we should when there’s an undercount,” said Reichelt.

The $3.4 million her department received in 2020 to fight addiction is spread thin, and even a relatively modest increase could make a big difference. The county can’t afford to build a detox center, and patients wait for weeks to get suboxone, a drug that reduces withdrawal symptoms, Reichelt said.

The Rio Arriba County Housing Authority, meanwhile, manages 54 public housing units, and assists another 25 families with rent vouchers. But the wait lists can be as long as five years, according to Reichelt.

Joey Garcia, a 32-year-old heroin addict who has been in and out of jail on drug charges, said he has struggled to get straight while on waiting lists for both subsidized housing and suboxone treatment.

“Somehow,” Garcia said, “I always relapse.”

NERVOUS TO ANSWER

The Rio Grande Valley in south Texas is a political netherworld. North of the border but south of immigration checkpoints, its four counties – Hidalgo, Cameron, Starr and Willacy – include informal communities known as colonias, often heavily populated with undocumented immigrants.

In Hidalgo, officials estimate they were undercounted by at least 10% in 2010, after just 56% of the population responded voluntarily. The Census Bureau estimated a more modest 5.4% undercount.

Either way, the undercounts reduced funding to the area’s Head Start and Low Income Heating and Energy Assistance (LIHEAP) programs, which cover only a fraction of eligible residents.

In Pueblo de Palmas, a colonia in Hidalgo County, Cristina, 35, qualifies for government-funded Head Start childcare for her four children, but only one was admitted. She asked that only her first name be used because she is an undocumented immigrant.

Both LIHEAP and Head Start are underfunded in the county. The former has a budget of $6 million, enough to serve 3-4% of qualifying households, says Jaime Longoria, the region’s community services director.

Head Start, which relies on population data to decide where to expand programs, can serve 3,700 kids in Hidalgo out of 22,000 who qualify, said Teresa Flores, the local Head Start director. An accurate count would help cover some of that gap, she said.

Cristina and her neighbor, Maria – also undocumented – both said they couldn’t remember filling out a census form in 2010 and that they were afraid to do so this year.

“I’m nervous someone will come to my house and take me away,” Maria said.

‘WE’RE BROKE’

In central Mississippi, voluntary participation in the 2010 census ranged between 45% and 60%. The rate in these areas so far this year is similar, according to Census data.

Lower funding from census undercounts has affected a crucial childcare program for low-income mothers in the nation’s poorest state, program officials said.

More than 112,000 Mississippi families are poor enough to qualify, but the program only has enough money to grant 20,000 to 25,000 vouchers, said Carol Burnett, who runs the nonprofit Mississippi Low Income Childcare Initiative.

Mississippi’s allotment under the Child Care and Development Block Grant that funds the program was $91.8 million in fiscal year 2019. An extra 1% of that total statewide – about $918,000 – could potentially serve hundreds more parents across the state, Burnett said, as the vouchers cover around $5,700 a year in expenses.

Tanisha Womack, 35, runs three daycare centers in Simpson and Smith counties, two of several counties in Mississippi that were among the hardest to count nationwide in 2010, according to the Reuters data.

Womack is certified to care for 152 children, but has just 72 children enrolled, she said, because many qualifying parents have been denied vouchers.

“We’re broke,” Womack said.

(Reporting by Nick Brown; Additional reporting by Grant Smith; Editing by Richard Valdmanis and Brian Thevenot)

COVID-19 again? Reinfection cases raise concerns over immunity

By Kate Kelland

LONDON (Reuters) – The case of a man in the United States infected twice with COVID-19 shows there is much yet to learn about immune responses and also raises questions over vaccination, scientists said on Tuesday.

The 25-year old from Reno, Nevada, tested positive in April after showing mild symptoms, then got sick again in late May with a more serious bout, according to a case report in the Lancet Infectious Diseases medical journal.

Scientists said that while known incidences of reinfection appear rare – and the Nevada man has now recovered – cases like his were worrying. Other isolated cases of reinfection have been reported around the world, including in Asia and Europe.

“It is becoming increasingly clear that reinfections are possible, but we can’t yet know how common this will be,” said Simon Clarke, a microbiology expert at Britain’s Reading University.

“If people can be reinfected easily, it could also have implications for vaccination programs as well as our understanding of when and how the pandemic will end.”

‘STILL DON’T KNOW ENOUGH’

The Nevada patient’s doctors, who first reported the case in a non peer-reviewed paper in August, said sophisticated testing showed that the virus strains associated with each bout of infection were genetically different.

“These findings reinforce the point that we still do not know enough about the immune response to this infection,” said Paul Hunter, a professor in medicine at Britain’s University of East Anglia.

Brendan Wren, a professor of vaccinology at the London School of Hygiene & Tropical Medicine, said the Nevada case was the fifth confirmed example of reinfection worldwide.

“The demonstration that it is possible to be reinfected by SARS-CoV-2 may suggest that a COVID-19 vaccine may not be totally protective,” he said. “However, given the (more than) 40 million cases worldwide, these small examples of reinfection are tiny and should not deter efforts to develop vaccines.”

(Reporting by Kate Kelland; Editing by Andrew Cawthorne)

More synchronized action needed to tackle COVID economic crisis, IMF’s Georgieva says

By Andrea Shalal and Marc Jones

WASHINGTON/LONDON (Reuters) – The international community must do more to tackle the economic fallout of the COVID-19 crisis, the head of the International Monetary Fund said on Monday, publicly calling on the World Bank to accelerate its lending to hard-hit African countries.

Some of the key events of the virtual and elongated annual meetings of the IMF and World Bank take place this week, with the most pressing issue how to support struggling countries.

“We are going to continue to push to do even more,” IMF Managing Director Kristalina Georgieva said during an online FT Africa summit.

“I would beg for also more grants for African countries. The World Bank has grant-giving capacity. Perhaps you can do even more… and bilateral donors can do more in that regard,” Georgieva said in an unusual public display of discord between the two major international financial institutions.

No immediate comment was available from the Bank.

Georgieva last week said the IMF had provided $26 billion in fast-track support to African states since the start of the crisis, but a dearth of private lending meant the region faced a financing gap of $345 billion through 2023.

The pandemic, a collapse in commodity prices and a plague of locusts have hit Africa particularly hard, putting 43 million more people at risk of extreme poverty, according to World Bank estimates. African states have reported more than 1 million coronavirus cases and some 23,000 deaths.

G20 governments are expected to extend for six months their Debt Service Suspension Initiative (DSSI) which has so far frozen around $5 billion of poorer countries’ debt payments, but pressure is on the main development banks and private creditors to provide relief too.

HOLDING ONTO GOLD RESERVES

Georgieva said the Fund was also pushing richer member countries to loan more of their existing Special Drawing Rights (SDR), the IMF’s currency, to countries that needed support most, and was “very committed” to finding a way forward for countries like Zambia now needing to restructure their debts.

The United States has blocked Georgieva’s early call for issuance of more SDRs, arguing that it would benefit mostly richer nations, not the developing countries that need it most.

Pledges to the Fund’s Poverty Reduction and Growth Trust, which supports low-income countries, have totaled $21 billion to date, including $14 billion in existing SDR holdings, but more resources were urgently needed, an IMF spokeswoman said.

The IMF chief dodged calls by civil society groups for the IMF to sell off some of its extensive gold reserves, saying the Fund viewed them as an important “financial buffer.”

Profit from selling less than 7% of the IMF’s gold could fund cancellation of all debt payments by the poorest countries to the IMF and World Bank for the next 15 months, the UK-based Jubilee Debt Campaign said in a new report issued Monday.

The IMF said its gold reserve of about 90.5 million ounces (2,814.1 metric tons) was worth about $137.8 billion at the end of December, compared to its historical cost of $4.4 billion.

Georgieva said countries in serious trouble must restructure their debts as soon as possible.

“This is the message for all countries in debt distress… If debt is not sustainable, please move towards restructuring, the sooner the better,” she said.

Georgieva said transparency in lending was critical for all parties, and welcomed what she called “encouraging” statements by China to move toward a more consolidated view of the debts held by the Chinese government and other institutions.

“I believe that now is the moment in this crisis, to make … transparency paramount and mandated to the extent possible everywhere,” she said.

(Reporting by Marc Jones in London, and Andrea Shalal and David Lawder in Washington; Editing by Tom Arnold, Ed Osmond and Andrea Ricci)

New U.S. COVID-19 cases rise 11% last week, Midwest hard hit

(Reuters) – The number of new COVID-19 cases rose 11% in the United States last week compared to the previous seven days, with infections spreading rapidly in the Midwest, which reported some of the highest positive test rates, according to a Reuters analysis.

Deaths fell 3% to about 4,800 people for the week ended Oct. 11, according to the analysis of state and county reports. Since the pandemic started, nearly 215,000 people have died in the United States and over 7.7 million have become infected with the novel coronavirus.

Twenty-nine out of 50 states have seen cases rise for at least two weeks in a row, up from 21 states in the prior week. They include the entire Midwest except Illinois and Missouri, as well as new hot spots in the Northeast, South and West.

In Idaho, 23.5% of more than 17,000 tests came back positive for COVID-19 last week, the highest positive test rate in the country, according to data from The COVID Tracking Project, a volunteer-run effort to track the outbreak. South Dakota, Iowa and Wisconsin also reported positive test rates above 20% last week.

For a third week in a row, testing set a record high in the country, with on average 976,000 tests conducted each day last week. The percentage of tests that came back positive for the virus rose to 5.0% from 4.6% the prior week.

The World Health Organization considers rates above 5% concerning because it suggests there are more cases in the community that have not yet been uncovered.

(Writing by Lisa Shumaker; Graphic by Chris Canipe; Editing by Tiffany Wu)

COVID-19 antibodies last at least three months; so do symptoms for many

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

COVID-19 antibodies last at least three months

People infected with COVID-19 develop antibodies targeting the new coronavirus that last for at least three months, according to two reports published on Thursday in Science Immunology. The two studies, together involving nearly 750 patients, both point to immunoglobulin G (IgG) antibodies, which start showing up well after an infection begins, as the longest-lasting. Researchers found IgG antibodies with two targets – a spike protein on the virus that helps it infect cells, and a part of the spike called the receptor binding domain (RBD) – lasted more than 100 days. While the protective effect of COVID-19 antibodies is not completely clear, Jen Gommerman of the University of Toronto, coauthor of the study, said her team also found levels of so-called neutralizing antibodies, which inactivate the virus, “appeared to be very stable.” The other study, from Harvard Medical School, reported similar findings. This means that a properly designed vaccine “should elicit a durable antibody response that has the potential to neutralize the virus,” Gommerman said. Her group also found that antibodies in saliva correlated with antibodies in blood, but at this point the saliva tests are not sensitive enough to replace blood tests.

COVID-19 symptoms linger for months for many

Three months after becoming ill, many COVID-19 patients still have symptoms, two studies confirm, and the more severe the initial infections, the higher the odds of persistent problems. In Spain, doctors checked back with 108 patients, including 44 who had been severely ill. At 12 weeks after diagnosis, 76% still reported after-effects, with 40% reporting three or more coronavirus-related health issues, doctors said in a paper posted on Thursday on medRxiv ahead of peer review. The most common complaints were shortness of breath, physical weakness, cough, chest pain, palpitations, and psychological and cognitive disorders. In a similar study of 233 U.S. COVID-19 patients – eight of whom had been severely ill – one in four still had symptoms 90 days after first feeling ill. Rates were higher for patients who had been sicker: 59.4% at 30 days and 40.6% at 90 days. “But even for very mild and initially asymptomatic cases, 14.3% have complications persist for 30 days or longer,” the authors reported on Sunday on medRxiv. In the U.S. study, the most common persistent symptoms were impaired smell and taste, difficulty concentrating, shortness of breath, memory loss, confusion, headache, heart palpitations, chest pain, pain with deep breaths, dizziness, and rapid heartbeat.

Remdesivir cut COVID-19 recovery time by 5 days

Final data from a large study of Gilead Sciences Inc’s antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days among hospitalized patients, one day faster than preliminary data had indicated, researchers reported on Thursday in The New England Journal of Medicine. The 1,062-patient study compared up to up to 10 days of therapy with remdesivir – now sold in some markets as Veklury – to a placebo. The average recovery time was 10 days among those who got the Gilead drug versus 15 days in the placebo group. Among patients requiring oxygen at the start, those taking remdesivir continued to need oxygen for an average of 13 days, compared to 21 days for patients who got a placebo. In a separate analysis looking just at patients who received oxygen, the drug appeared to reduce the risk of death over the next month by 70%. “We now have data suggesting that giving remdesivir to patients on oxygen may significantly reduce their chances of death compared to other subgroups,” Dr. Andre Kalil, an infectious disease expert at the University of Nebraska Medical Center and the study’s lead investigator, said in a news release.

Coronavirus rarely travels from mother to newborn

Transmission of the new coronavirus from mothers to newborns is rare, doctors from New York-Presbyterian/Columbia University Irving Medical Center reported on Monday in JAMA Pediatrics. They studied 101 babies born to 100 mothers with COVID-19, including 10 whose mothers had been severely ill. Almost all of the babies tested negative for the virus, while tests in two newborns had indeterminate results. If these two indeterminate results are considered positive, the overall incidence of transmission was 2.0%. Even with a 2% transmission rate, “none of our babies exhibited clinical symptoms of COVID-19, either during their newborn nursery stay or during … the first few weeks of life,” coauthor Dr. Dani Dumitriu told Reuters Health by email. Roughly 90% of the newborns were breastfed at least partially. “As the country heads into what looks like a second wave of the COVID-19 pandemic, it is important to know that separation of affected mothers from their newborns may not be warranted, and direct breastfeeding appears to be safe,” study coauthor Dr. Melissa Stockwell said.

(Reporting by Nancy Lapid, Julie Steenhuysen and Will Boggs; Editing by Bill Berkrot)